BOSTON, June 24, 2021 /PRNewswire/ — Valo Health, LLC (“Valo”), the know-how firm constructed to remodel the drug discovery and growth course of utilizing human-centric knowledge and synthetic intelligence (“AI”), right this moment introduced the appointment of Judy Lewent to its Board of Administrators and as chair of its Audit Committee. Lewent, a extremely regarded govt with over 30-years of in depth expertise within the international pharmaceutical and know-how industries, was most lately a Non-Government Impartial Director of GlaxoSmithKline and is the previous Chief Monetary Officer of Merck & Co., Inc., the place she was primarily chargeable for finance, company growth and strategic planning.
“Judy brings unparalleled expertise inside the finance, know-how and pharmaceutical realms. We’re thrilled to convey aboard such a well-respected chief,” mentioned David Berry, CEO of Valo Well being. “Her deep expertise throughout each tech and life science speaks to Valo’s ethos, with that uncommon potential to function throughout each fields, which we consider to be important to reworking drug discovery and growth. Her acute enterprise acumen, strategic imaginative and prescient, and talent to combine economics, finance, statistics, and laptop science make her an incredible asset to our rising firm. I significantly sit up for working together with her and having the good thing about her insights.”
“I am happy to be becoming a member of Valo at such a vital juncture, as they hit their stride in constructing a platform that’s properly positioned to speed up the invention and growth of latest medication,” Lewent mentioned. “The mix of Valo’s management, compute capabilities, and knowledge analytics are a testomony to why it’s vital that we spend money on new methods to remodel the legacy strategy within the pursuit of attaining higher outcomes on behalf of sufferers.”
Over her 27 years at Merck, Lewent was chargeable for worldwide finance, company growth, licensing, and strategic planning. She additionally led the Johnson & Johnson, Merck Shopper Prescription drugs, and Merial (Merck and Sanofi-Aventis) three way partnership relationships, in addition to Merck’s relationships with Astra and DuPont. As well as, she served as chair of Merck Capital Ventures and was a member of Merck’s govt committee.
Lewent is at the moment on the board of administrators of Motorola Options, and she or he has beforehand served on the boards of biotech and tech authorities Thermo Fisher Scientific and Dell. As well as, she is a life member of the MIT Company and a member of the American Academy of Arts & Sciences. In 2000, CFO Journal introduced her with the CFO Excellence Award within the Revenue Growth category.
Lewent earned a B.S. in economics from Goucher School in 1970 and an M.S. in administration from MIT’s Sloan College of Administration in 1972. She obtained an honorary doctorate of humane letters from Goucher School in 1998, an honorary physician of engineering from Stevens Institute of Expertise in 2000, and an honorary doctorate of science from the New Jersey Institute of Expertise in 2004.
About Valo Well being
Valo Well being, LLC (“Valo”) is a know-how firm constructed to remodel the drug discovery and growth course of utilizing human-centric knowledge and synthetic intelligence (“AI”) pushed computation. As a digitally native firm, Valo goals to totally combine human-centric knowledge throughout all the drug growth lifecycle right into a single unified structure, thereby accelerating the invention and growth of life-changing medication whereas concurrently decreasing the fee, time, and failure charge. The corporate’s Opal Computational Platform™ consists of an built-in set of capabilities designed to remodel knowledge into helpful insights which will speed up discoveries and allow Valo to advance a strong pipeline of packages throughout cardiovascular metabolic renal, oncology, and neurodegenerative illness. Based by Flagship Pioneering and headquartered in Boston, MA, Valo additionally has workplaces in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To be taught extra, go to www.valohealth.com.
Extra Data and The place to Discover It
This doc pertains to a proposed transaction between Valo and Khosla Ventures Acquisition Co. (“KVAC”). This doc doesn’t represent a suggestion to promote or trade, or the solicitation of a suggestion to purchase or trade, any securities, nor shall there be any sale of securities in any jurisdiction by which such supply, sale or trade can be illegal previous to registration or qualification underneath the securities legal guidelines of any such jurisdiction. KVAC intends to file a registration assertion on Kind S-4 with the SEC, which can embody a doc that serves as a prospectus and proxy assertion of KVAC, known as a proxy assertion/prospectus. A last proxy assertion/prospectus will likely be despatched to all KVAC shareholders. KVAC additionally will file different paperwork concerning the proposed transaction with the SEC. Earlier than making any voting determination, buyers and safety holders of KVAC are urged to learn the registration assertion, the proxy assertion/prospectus and all different related paperwork filed or that will likely be filed with the SEC in reference to the proposed transaction as they turn into obtainable as a result of they’ll comprise necessary details about the proposed transaction.
Traders and safety holders will be capable of acquire free copies of the registration assertion, the proxy assertion/prospectus and all different related paperwork filed or that will likely be filed with the SEC by KVAC by means of the web site maintained by the SEC at www.sec.gov.
The paperwork filed by KVAC with the SEC additionally could also be obtained freed from cost at KVAC’s web site at https://khoslaventuresacquisitionco.com/kvsa or upon written request to Secretary at Khosla Ventures Acquisition Co., 2128 Sand Hill Street, Menlo Park, California 94025.
Members in Solicitation
KVAC and Valo and their respective administrators and govt officers could also be deemed to be members within the solicitation of proxies from KVAC’s shareholders in reference to the proposed transaction. A listing of the names of such administrators and govt officers and data concerning their pursuits within the enterprise mixture will likely be contained within the proxy assertion/prospectus when obtainable. Chances are you’ll acquire free copies of those paperwork as described within the previous paragraph.
This doc comprises sure forward-looking statements inside the that means of the federal securities legal guidelines with respect to the proposed transaction between Valo and KVAC. These forward-looking statements typically are recognized by the phrases “consider,” “mission,” “count on,” “anticipate,” “estimate,” “intend,” “technique,” “future,” “alternative,” “plan,” “could,” “ought to,” “will,” “would,” “will likely be,” “will proceed,” “will possible end result,” and comparable expressions. Ahead-looking statements are predictions, projections and different statements about future occasions which are based mostly on present expectations and assumptions and, because of this, are topic to dangers and uncertainties. Many elements may trigger precise future occasions to vary materially from the forward-looking statements on this doc, together with however not restricted to: (i) the danger that the transaction might not be accomplished in a well timed method or in any respect, which can adversely have an effect on the worth of KVAC’s securities, (ii) the danger that the transaction might not be accomplished by the enterprise mixture deadline and the potential failure to acquire an extension of the enterprise mixture deadline if sought by both get together, (iii) the failure to fulfill the circumstances to the consummation of the transaction, together with the approval of the adoption of the Settlement and Plan of Merger, dated as of June 9, 2021 (the “Merger Settlement”), by and amongst KVAC, Valo, Valo Well being, Inc., a Delaware company and a direct wholly owned subsidiary of Valo and Killington Merger Sub Inc., a Delaware company and a direct wholly owned subsidiary of KVAC, by the shareholders of KVAC, the satisfaction of the minimal belief account quantity following any redemptions by KVAC’s public shareholders and the receipt of sure governmental and regulatory approvals, (iv) the shortage of a 3rd get together valuation in figuring out whether or not or to not pursue the proposed transaction, (v) the lack to finish the PIPE transaction, (vi) the prevalence of any occasion, change or different circumstance that would give rise to the termination of the merger settlement, (vii) the impact of the announcement or pendency of the transaction on Valo’s enterprise relationships, working outcomes, and enterprise typically, (viii) dangers that the proposed transaction disrupts present plans and operations of Valo, (ix) the result of any authorized proceedings that could be instituted in opposition to Valo or in opposition to KVAC associated to the merger settlement or the proposed transaction, (x) the flexibility to take care of the itemizing of KVAC’s securities on a nationwide securities trade, (xi) modifications within the aggressive and controlled industries by which Valo operates, variations in working efficiency throughout rivals, modifications in legal guidelines and rules affecting Valo’s enterprise and modifications within the mixed capital construction, (xii) the flexibility to implement enterprise plans and different expectations after the completion of the proposed transaction, and establish and understand extra alternatives, (xiii) the danger of downturns and a altering regulatory panorama within the extremely aggressive drug discovery and growth trade, and (ix) prices associated to the transaction and the failure to understand anticipated advantages of the transaction or to understand estimated professional forma outcomes and underlying assumptions, together with with respect to estimated shareholder redemptions. The foregoing record of things isn’t exhaustive. It’s best to rigorously think about the foregoing elements and the opposite dangers and uncertainties described within the “Danger Components” part of the registration assertion on Kind S-4 mentioned above and different paperwork filed by KVAC on occasion with the SEC. These filings establish and deal with different necessary dangers and uncertainties that would trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and Valo and KVAC assume no obligation and don’t intend to replace or revise these forward-looking statements, whether or not because of new data, future occasions, or in any other case. Neither Valo nor KVAC provides any assurance that both Valo or KVAC, or the mixed firm, will obtain its expectations.
SOURCE Valo Well being, LLC